Platform vs asset, partnering vs going-it-alone, fundraising cadence, regulatory strategy, hiring scientific leadership. Founder-level decisions only — never medical, clinical, or scientific advice.
When do you focus on a single asset, and when do you sell the platform? The Strategist and Investor synths debate the dilution math against the optionality.
Pharma partnership, co-development deal, or full ownership through Phase 2? The CFO and Strategist surface the trade-offs your BD team will rationalize away.
Biotech capital is structural — when to raise, how much, from whom, at what dilution. The Investor and CFO synths argue with each other so you don't over-raise or under-raise.
When do you hire a CSO, a CMO, a head of regulatory? The Empath and Strategist work through the org-design call most biotech founders defer too long.
Real questions. Multiple expert perspectives. Every time.
“Should we license our platform to big pharma now or push to Phase 1 ourselves?”
“When do we raise our crossover round vs push for a strategic deal first?”
“Should we hire a CMO before or after our IND filing?”
“How do we structure a co-development deal that doesn't cap our future exit?”
“Should we pursue a SPAC, a traditional IPO, or stay private longer?”
“When do we move from a platform pitch to an asset-led pitch with investors?”
Each expert thinks independently — they won’t just agree with each other.
The Strategist
Maps competitive dynamics and strategic options across multi-year horizons.
The Regulator
Reads the rules of the field you’re playing on before you commit.
The CFO
Pressure-tests unit economics, runway, and capital allocation.
The Scientist
Frames decisions as testable hypotheses with clear falsification criteria.
The Investor
Thinks like a board, an LP, and a downstream acquirer at once.
A synthesized recommendation from your team of experts — not just opinions, but structured analysis.
Moderate Agreement
Key Recommendations
Synthesized Recommendation
Push for the strategic partnership now rather than the crossover round. The deal terms get worse after Phase 1 data — better to lock in the option value while the platform story still drives valuation.
Full analysis continues with detailed reasoning, trade-offs, and next steps...
Watch Out For
Expert Opinions
“Biotech founders spend years on the science and minutes on the deal structure that determines whether they keep the company. A boardroom is where you correct that imbalance — before the term sheet, not after.”
SynthBoard is for founder business decisions about biotech companies. It does not give scientific, clinical, medical, regulatory, or investment advice and is not a substitute for licensed professionals.
Biotech operates on 7-12 year horizons. SynthBoard's synths reason in those timeframes — not the quarterly cadence built for SaaS.
The Investor synth thinks like a board and a downstream acquirer. The Regulator synth frames the FDA strategic posture. Together: the trade-offs biotech founders normally pay $50K of advisors to assemble.
IP-sensitive strategy work stays confidential. Sessions are encrypted, never used for external training, and shared only when you explicitly invite collaborators.
The questions people ask before they sign up.
No. SynthBoard is built for founder business decisions — fundraising, partnering, hiring, regulatory strategy, IPO timing. It does not provide scientific, clinical, medical, or regulatory advice and is not a substitute for licensed professionals in any of those domains.
No. These synths help you frame the strategic shape of a decision — when to file, what to prioritize, what to ask your specialists. The actual regulatory submission, scientific design, and primary-source work stays with your specialist consultants and counsel.
All three — the motion is similar but the synth weight shifts. Therapeutics founders lean hard on the Regulator and Investor. Diagnostics lean on the CFO and Strategist (reimbursement-driven). Platforms lean on the Strategist and Investor (partnership economics).
It runs both arguments in parallel. The Strategist will argue for platform optionality; the Investor will pressure-test what the market actually pays for. You get the trade-offs forced into the open — not a single optimistic recommendation.
It helps you frame what to negotiate for — change-of-control, milestone triggers, opt-out gates. The actual term sheet review and negotiation stays with your biotech BD counsel and dealmakers.
Sessions are encrypted at rest, never used for external model training, and accessible only to you unless you explicitly share. That said — for the most sensitive IP (specific molecule structures, unpublished data), founders typically frame the decision in higher-level terms.
Adjacent decisions, audiences, and methods inside SynthBoard.
Adjacent industry with similar regulated-business decision shapes.
ExploreAnother capital-intensive, long-cycle deep-tech industry.
ExploreThe recurring decision biotech founders revisit every 18 months.
ExplorePharma partnerships are some of the most consequential decisions a biotech makes.
ExploreThe investor lens biotech founders need before every board meeting.
ExploreSurface the failure modes before the next IND or partnership commitment.
Explore250 bonus credits at signup. 150 free every month. No card required.